Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic Leukemia
for T-cell Prolymphocytic Leukemia
Drug: Ruxolitinib
1 location in Houston
Sponsor: M.D. Anderson Cancer Center
Sex: All·Age: 18+
Code: NCT07311746·Phase 1, Phase 2·Recruiting·Listed Dec 2025